Multiple Sclerosis - GK Flashcards
(107 cards)
An immunologic disorder marked by chronic inflammation of the central nervous system (CNS)
What disease is this?
Multiple Sclerosis
In MS, mononuclear cells infiltrate the _______ space between arteries and veins and the pia mater, axons are _______ and destroyed, and immunoreactive changes in ______ cells result in the formation of ______ in multiple areas of the CNS.
perivascular
demyelinated
glial
plaques
what is the key to the diagnosis of MS?
dissemination of these plaques in time and space
What are the 4 types of MS?
- relapsing-remitting RR
- primary-progressive PP
- secondary-progressive SP
- progressive-relapsing or primary progressive with activity PR/PP
MS tx falls into what 3 categories?
- exacerbations: corticosteroids
- Disease modifying therapies DMT
- symptomatic therapies for spasticity, bladder and sensory sx, fatigue.
What are the 5 FDA approved 1st gen agents used to tx MS?
- Avonex
- Rebif
- Interferon-B1b
- Pegylated Interferon-B1b
- Glatiramer acetate
MOA: alters expression and response to surface antigens enhancing immune cell activities
Dosage: IM
Avonex (Interferon-B1a)
MOA: alters expression and response to surface antigens enhancing immune cell activities
Dosage: SQ
Rebif (Interferon B-1a)
MOA:
- Augments suppressor cell function and reduce IFN-γ secretion by activated lymphocyte
- Macrophage-activating effect
- Down regulates the expression of IFN-γ–induced class II MHC gene products on antigen-presenting glial cells
- IFN suppresses T-cell proliferation and may decrease blood–brain barrier permeability
Dosage: SQ
Interferon B-1b
MOA: alters expression and response to surface antigens enhancing immune cell activities
Dosage: SQ
Pegylated Interferon-B-1a
MOA: mimics antigenic properties of myeling binding protein (MBP) and inhibits binding of MBP peptides to T-cell receptor complexes.
Dosage: SQ
Glatiramer acetate
Indication and Dose: relapsing, orally
MOA: sequesters circulating lymphocytes into secondary lymphoid organs & reduces infiltration of T-lymphocytes & macrophages into the CNS.
Fongolimod
sequesters like a cowboy
MOA: inhibits dihydroorotate dehydrogenase = prevent proliferation of peripheral lymphocytes (T&B cells). Reduces activation of lymphocytes in CNS, reduces inflammation and demyelination.
Dose & Indication: relapsing, orally
Which drug?
Teriflunomide
Dose & Indication: relapsing, orally
MOA: Unknown-invitro nicotinic acid receptor agonist, invitro activator of Nrf2 pathway involved in cellular response to oxidative stress
Dimethyl Fumarate
“When you are di-ing, you need Oxygen and you fume if you don’t get it”
AKA
cellular response to oxidative stress
Dose & Indication: RRMS, 1st dose: IV for 5 days 2nd dose: IV for 3 days. Administer 2nd dose 12 mo after 1st tx.
Which drug?
Alemtuzumab
What kind of MS would you use Ocrelizumab for?
relapsing or progressive
ADE: depression, flu-like sx, leukopenia, injection site rxn
Monitor: electrolytes, CBC, [LFT’s at baseline, 1 mo, and every 3 mo for a year, and every 6 mo thereafer], thyroid function, LVEF.
What drug is this?
Avonex (Interferon-B1a)
Indication: Relapsing form of MS
**low potency
**avoid use in untreated severe depression**
What drug is this?
Avonex (Interferon B-1a)
ADE: depression, flu-like sx, leukopenia, injection site rxn
Monitor: electrolytes, CBC, [LFT’s at baseline, 1 mo, and every 3 mo for a year, and every 6 mo thereafer], thyroid function, LVEF.
Rebif (Interferon-B-1a)
Indication: Relapsing form of MS
_**high potency_
_**avoid use in untreated severe depression**_
What drug is this?
Rebif (Interferon-B1a)
ADE: depression, flu-like sx, leukopenia, injection site rxn
Monitor: more frequent injection site rxns reported
What drug is this?
Interferon B-1b
Indication: Relapsing form of MS
**high potency, pregnancy category C
What drug is this?
IFN Beta 1b
ADE: depression, flu-like sx, leukopenia, injection site rxn
Monitor: electrolytes, CBC, [LFT’s at baseline, 1 mo, and every 3 mo for a year, and every 6 mo thereafer], thyroid function, LVEF.
What drug is this?
Pegylated IFN Beta 1a